Top Markets
#1 Purr Purr +54.61%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +47.53%
#4 Non-Playable Coin Non-Playable Coin +34.14%
#5 ApeX ApeX +28.99%
#6 Cash Cat Cash Cat +26.76%
#7 Kinetiq Kinetiq +24.66%
#8 Morpho Morpho +24.02%
#9 OriginTrail OriginTrail +21.34%
#10 StonkBroker StonkBroker +20.82%
Coin of the day
Purr Purr
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA
Peringkat dalam Saham #21165
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Harga Saham
$4.83
Terakhir disinkronkan: 2026-08-21
Kapitalisasi Pasar
$113.30M
Perubahan (1 hari)
-0.62%
Perubahan (1 tahun)
-29.59%
Negara
US
Perdagangan Coya Therapeutics, Inc. (COYA)

Kategori

Healthcare
Laba untuk Coya Therapeutics, Inc. (COYA)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Coya Therapeutics, Inc., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Coya Therapeutics, Inc. dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH